SANOFI: directors' dealings · France · AMF

About SANOFI

Sanofi is a French global healthcare leader focused on the discovery, development, manufacturing and commercialization of medicines and vaccines. The company is listed in Paris and identified by ISIN FR0000120578. Its investment case is built on a science-led biopharma platform with a strong emphasis on innovation across major therapeutic areas, including immunology, rare diseases, neurology, oncology and vaccines. Sanofi currently describes itself as an R&D-driven, AI-powered biopharmaceutical company, with a strategy aimed at accelerating growth through breakthrough science, pipeline expansion and the launch of new products. The company traces its roots to 1973, when it was created in France, although its heritage extends much further back through numerous predecessor businesses in healthcare whose origins date to the 18th and 19th centuries. Sanofi marked the 50th anniversary of its creation in 2023, underscoring the depth of its industrial and scientific legacy. Over time, this heritage has helped Sanofi become one of Europe’s most established healthcare groups, with a broad international footprint and a long history of corporate consolidation, research capability building and portfolio expansion. Operationally, Sanofi’s core businesses span prescription medicines, vaccines and innovative specialty therapies. Dupixent is one of the group’s flagship products and remains a major growth driver, while newer launches such as Tzield and Altuviiio are broadening the company’s commercial base. Sanofi also has a longstanding vaccine franchise, with historical strengths in injectable polio vaccines as well as influenza, meningitis and rabies vaccines. The company states that its vaccine portfolio protects hundreds of millions of people worldwide, highlighting both its scale and its public-health relevance. From a geographic standpoint, Sanofi operates globally, with a significant presence across Europe, North America and major emerging markets. Its integrated model combines research, manufacturing and commercial activities in numerous countries, supporting worldwide access to its medicines and vaccines. Recent financial updates indicate strong commercial momentum, driven by launches and key franchises. Strategically, Sanofi has also announced a shift toward a more focused, science-driven biopharma profile, including its intention to sell a controlling stake in Opella, its consumer healthcare business. This move simplifies the group’s structure and reinforces its positioning as a high-value, innovation-led pharmaceutical company.